Medsyn (Chengdu) Biotechnology Co., Ltd
About Medsyn (Chengdu) Biotechnology Co., Ltd
-
Country/Region:China
-
On CPHI since:2023
Products from Medsyn (Chengdu) Biotechnology Co., Ltd (3)
-
Product Bavdegalutamide
Given these mechanisms of resistance, our goal is to eliminate the AR protein using the PROteolysis TArgeting Chimera (PROTAC) technology. Here we report an orally bioavailable small molecule ARV-110 that leads to ubiquitination and degradation of AR. ARV-110 completely degrades AR in all cell lines ... -
Product Orforglipron
Obesity is a major risk factor for many leading causes of illness and death worldwide. Data are needed regarding the efficacy and safety of the nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron as a once-daily oral therapy for weight reduction in adults with obesity.In this phase 2, ... -
Product Pirtobrutinib
Pirtobrutinib, a highly selective kinase inhibitor, utilizes a novel binding mechanism and is the first and only FDA approved non-covalent (reversible) BTK inhibitor. Jaypirca can reestablish BTK inhibition in MCL patients previously treated with a covalent BTK inhibitor (ibrutinib, acalabrutinib, or zanub...
